The United States FDA approved three promising biomarkers of PCa, including the urinary Progensa Prostate Cancer Antigen 3 (PCA3) assay as well as a serum prostate health index (PHI) assay and the four-kallikrein (4Kscore). Here, PCA3 is linked to posterior cortical atrophy.